Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
55 hedge funds and large institutions have $40.5M invested in Cidara Therapeutics in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 22 reducing their positions, and 21 closing their positions.
150% more call options, than puts
Call options by funds: $155K | Put options by funds: $62K
0.14% less ownership
Funds ownership: 2.22% → 2.08% (-0.14%)
11% less funds holding
Funds holding: 62 → 55 (-7)
29% less capital invested
Capital invested by funds: $56.6M → $40.5M (-$16.1M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
55% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.56M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$1.28M |
| 3 |
Millennium Management
New York
|
+$1.09M |
| 4 |
Renaissance Technologies
New York
|
+$503K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$370K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.09M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.24M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$982K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$639K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$526K |
CDTX Hedge Fund Activity: Q2 2021 in Review
55 of the 5,766 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2021, worth a combined $40.5M — down 29% from $56.6M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CDTX and 14 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 10 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $2.56M. The largest seller was BlackRock, cutting an estimated $3.09M.
- 55 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2021, down from 62 in Q1 2021.
- Funds reported $40.5M of Cidara Therapeutics stock for Q2 2021, down 29% quarter-over-quarter.
- 14 funds opened new Cidara Therapeutics positions in Q2 2021 and 21 closed out, a net change of -7 holders.
- The largest Cidara Therapeutics buyer in Q2 2021 was Stonepine Capital Management, an estimated $2.56M added.
- The largest Cidara Therapeutics seller in Q2 2021 was BlackRock, an estimated $3.09M sold.
Based on aggregated 13F filings for Q2 2021.